• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JUNE 27, 2002

Pfizer: Merger picture

Pfizer Inc. emerged as the world's largest pharma company in early 2000, when it snatched Warner Lambert from the clutches of rival suitor American Home Products (AHP). A US$ 90 bn acquisition of Warner Lambert was the largest ever in the history of global pharma industry. The merged entity now has sales close to US$ 30 bn with highest R&D budget in the pharma industry.

With Warner came cholesterol-fighter Lipitor, the drug market's No. 1 seller with $6 bn in annual revenues, apart from other major brands. Following the global merger, Pfizer India also decided to merge Warner Lambert subsidiary, Parke Davis with itself. The company is expected to announce the merger ratio today. We expect the ratio to be 1:3 (i.e. 3 shares of Parke Davis for every share of Pfizer).

Pfizer-Parke Davis - A robust entity
The merged entity in India would have robust financial numbers with sales expected around Rs 6 bn, leading to a position in the list of top five domestic pharma players and a combined market share of 3.2% in the domestic industry.

Rs m Pfizer* Parke Davis** Merged Entity***
Net Sales 3,206 2,134 5,755
Operating Margins (%) 7.2% 14.0% 11.8%
Net Profit 475 250 812
EPS (Rs.) 20.3 20.8 29.5
*- Latest available 12 month results **- Annualised 12 months results
***- Expected numbers for 12 months ending Nov'02
Apart from financial consolidation, the merger with Parke Davis is expected to add significant brands to the company's already impressive product portfolio. Pfizer would inherit brands such as Benadryl, Gelusil and Listerine from Parke Davis.



Particulars Pfizer Parke Davis Merged
ORG Rank 11 23 5
No. of Products 24 54 78
Sales per brand (Rs m) 134 40 74
As shown in the above table, while Pfizer brings on the table a small portfolio of mega brands, Parke Davis, brings a larger portfolio of products. While on one hand, the merger would help Pfizer create a strong hold in the OTC segment; the companyís aggressive marketing field force would have a large product portfolio to push. Pfizerís marketing team is considered to be the best in the industry. Barring Benadryl, there is little overlap in the product profiles of both the companies even in common therapeutic segments. Even after the merger, the sales value per brand for Pfizer is expected to be impressive, which clearly vouches for its strong brand portfolio.

Both Pfizer and Parke Davis have introduced few new products due to weak patent laws and competition in the formulations market in the domestic market. Considering the parentís stand on new product introductions, the situation is not expected to improve. The company now seems to be tackling this by tying-up with local pharmaceutical companies. The tie -up with Shanta Biotech, to market the latterís hepatitis-B vaccine was a unique combination of innovative product and strong marketing. The company is also awaiting other products from the Shanta Biotech stable.

Pfizer- Few but strong brands
Company Ranking in
terms of sales*
No. of
Products
Sales/Product
(Rs m)
Aventis 6 55 94
Pfizer 5 78 74
GlaxoSmithKline 1 210 53
Ranbaxy 2 237 35
Nicholas Piramal 4 217 25
Cipla 3 358 21
*- Expected rankings post Pfizer- Parke Davis merger

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407